| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3868745a86f52a211bd9026c293ebae8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-025 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9ec07d059ab1e4a5076bb74c6594740
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8429e91c41274d8b4f332907cacf1d89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bdee1bc3fffe22341965767aec31287
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1d68a0a2ae1db2d807379d9c9f8c7de |
| publicationDate |
2019-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3482204-A1 |
| titleOfInvention |
Method for determining the risk of developing arthritis |
| abstract |
The invention provides a method of determining the risk of developing rheumatoid arthritis in a subject comprising the steps of determining in a biological sample from said subject the number and/or frequency of dominant BCR clones, and determining the risk of developing rheumatoid arthritis based on said number of dominant BCR clones, wherein an increase of said number of dominant BCR clones and/or a higher frequency of at least one dominant BCR clone compared to a healthy control indicates an increased risk. In a preferred embodiment, said increased risk is indicated when at least 0.5% of the total number of BCR clones is a dominant BCR clone. |
| priorityDate |
2016-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |